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Summary
In the last decades, there have been important developments in the method-
ology of statistical designs in phase II clinical trials. Those designs either optimize
the expected sample size or the total number of sample size, under the constraints
of some system error rates, such as type I error and type II error. This thesis briefly
discusses the relationship among the error rates and provides comparisons among
the optimal designs under different error rates. Moreover, this thesis discusses the
effects of prior-misspecifications. Two widely used designs are considered, Bayesian
sequential design and sequential Bayesian decision theoretic design. Our findings
are, Bayesian sequential designs are robust to misspecifications of prior variances
and they are robust to the misspecifications of prior means if the prior variances
are large or true prior means are large; the sequential Bayesian decision theoretic
designs are robust to the misspecifications of prior means and misspecifications
of prior variances, if the true prior means or the true prior variances are large
respectively.
xiii




Clinical trials have played dominant and expanding roles in the evaluation of new
treatments during the passing decades of years. There were important develop-
ments in the methodology of statistical designs as well, especially in the oncologi-
cal field. Generally, clinical trials consist of three phases. Phase I is the beginning
phase of a clinical trial, which is carried out to determine the maximum tolerated
dose of patients for the drug or treatment in study. This phase is essentially im-
portant, because most of the cancer treatments or other treatments are delivered
at the maximum dose to maximize the effects. Usually, three to six patients are
tested for each dose level. Phase II is the core of clinical trials. The purpose is to
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determine whether a drug has anti-disease activity. This phase can be one stage,
two stages or more, even continuous sequence. This phase is quite crucial and
deserves much statistical research. More descriptions will be made in the following
chapters. After phase II study, only those treatments which show sufficient active
effects can be accepted as promising ones and tested in the next phase, otherwise
the trials are stopped and the new treatments are rejected as nonpromising. At
Phase III, the new treatment will be tested on a large sample size. Finally, if the
new treatment performs well in all the three phases, it will be put into production.
From the above descriptions, it is obvious that phase II studies play a pivotal role
in the treatment development process. The role is basically selecting from many
new treatments created by experimental research and those selected will be fur-
ther investigated and possibly used thereafter for clinical purposes. In this step,
financial limits and time limits require the designs cost less number of patients, so
at the same time there exists the risk to reject promising treatments and accept
nonpromising treatments. Therefore, phase II statistical designs are always im-
proved to the directions of decreasing either expected sample size or total sample
size under the constraints of error rates.
Various papers have been published on phase II study in the last four decades.
The designs can be classified in many ways. First, the designs are distinct between
two particular situations. One case, only one new candidate treatment for test;
the other case, many new treatments are simultaneously available for test. Second,
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designs could be classified as controlled and uncontrolled. In the controlled cases,
each new treatment is evaluated at the same time for comparison and in the uncon-
trolled cases, only the new treatment is tested. Third, the designs can be classified
by different number of stages. The designs are named one-stage designs, if there is
no stop during the whole trial; the designs are named two-stage designs, if there
is one stop during the trial, and even to sequential designs, if the trials stop by
each response of patient. Finally, the phase II designs are usually classified by the
different statistical method as three kinds, frequentist designs, Bayesian designs
and Bayesian theoretic designs.
Many designs are named as optimal designs under the constraints of different error
rates. This thesis summarizes different error rates and iterate their converting rela-
tionships. An example is given to compare the results under different constraints.
Moreover, for any Bayesian design, the prior distribution always plays a funda-
mental role to the conclusions of design, so this thesis as well detects the effects of
prior-misspecifications on two widely used designs, Bayesian sequential design and
sequential Bayesian decision theoretic design.
1.2 Organization of This Thesis
This thesis begins with the introduction of phase II clinical designs. In chapter 2,
three kinds of existed phase II designs are reviewed, and comparisons are made.
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Different designs focus on different statistics for optimization, either expected sam-
ple size or total sample size, under different constraints of error rates. In chapter
3, we make a further discussion about the error rates and sample sizes of different
designs. In fact, the type I error and type II error, probability to reject and accept,
and probability of false positive and false negative can be converted to each other.
In chapter 3, we also compare the optimal designs under different constraints of er-
ror rates. In chapter 4, we detect the effects of prior-misspecifications on Bayesian
sequential designs and sequential Bayesian decision theoretic designs, which are
two widely used designs. As a result, Bayesian sequential designs are robust to
misspecifications of prior variances and they are robust to the misspecifications
of prior means if the prior variances are large or true prior means are large; the
sequential Bayesian decision theoretic designs are robust to the misspecifications
of prior means and misspecifications of prior variances, if the true prior means or
the true prior variances are large respectively. Otherwise, the designs are sensitive.
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Chapter 2
Review of Fundamental Designs
This chapter briefly reviews three kinds of fundamental designs, frequentist designs,
Bayesian designs and Bayesian decision theoretic designs.
2.1 Frequentist Designs
Two-stage frequentist designs divide Phase II clinical trials into two stages. It is
at some middle point of the test, we stop and collect the outcome information of
the patients. If the result shows the new treatment is efficacious, we will let the
test go on, otherwise, we will stop the test and reject the treatment immediately.
Therefore, compared to one-stage designs, the advantages of two-stage design is
the test will be stopped earlier, if the new treatment is not promising.
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2.1.1 Optimal and Minimax Designs
Simon (1989) provides very popular uncontrolled two-stage designs to test whether
a new treatment is promising or nonpromising in Phase II clinical trials. There
are two main methods of this kind of design. One focuses on minimizing the total
number of sample size in two stages, the other one focuses on minimizing the
expected sample size. But both of them avoid to deciding gain functions or cost
functions. Acceptance of the new treatment is possible only after the second stage.
Suppose we have a new treatment E, the outcomes are binary, failure and success
on each patient. The minimum and maximum number of patients to be tested
is nmin and nmax respectively. The design need to provide cutoff criteria for real
testing. The design is base on the hypothesis test:
H0 : pE ≤ p0
H1 : pE ≥ p1
pE is the true success probability of the new treatment, p0 is some undesirable value
of success probability and p1 is some desirable value of success probability. p0 and
p1 are derived from the empirical study of standard treatment. We use Yi = 1 or





During the trial, the probability to reject E after stage 1 is
PET = B(r1, n1, pE) (2.2)
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piE(1 − pE)n1−i is the cumulated probability of bi-
nomial distribution, r1 is the least number of success among n1 patients in stage
1, if the new treatment is promising. If the total number of success in stage 1 is
no less than r1, the design will go on to test additional n2 patients in stage 2, so
n = n1 + n2 is the total number of patients for the two stages.
Overall, the probability to reject E is
λ = B(r1, n1, pE) +
min[n1,r]∑
x=r1+1
b(x, n1, pE)B(r − x, n2, pE) (2.3)








For the optimal design, the expected sample size EN = n1 + (1− PET )n2 is min-
imized and for the Minimax design, the total sample size n is minimized. n1 and
the cutoff boundaries, r1 of n1, r of n are decided by either minimizing expected
sample size or minimizing n, under the constraints of type I error and type II error.
Type I error=P(accept E | pE ≤ p0) ≤ β
Type II error=P(reject E | pE ≥ p1) ≤ α
where α and β are given according to the accurate requirements. Though com-
pared with one stage designs, two-stage designs have relatively small total number
of sample size or expected number of sample size, they are not powerful enough to
warrant the test to be end as soon as possible. There is still some area to make fur-
ther improvement. This is the motivation of sequential designs, that is to observe
the result after each patient has an outcome.
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2.1.2 Optimal Two-stage Design for More Than One New
Treatments
The previous Simon’s two-stage designs are uncontrolled clinical trials to decide
whether one new treatment E is promising according to some success probability.
In practise, some other situations may also happen. If we want to test more than
one new treatments for one disease, the object of the test is to select the one
most promising and decide whether the best one makes significant improvement
compared with the standard treatments.
Thall, Simon and Ellenberg carried out the two-stage selection and testing designs
for comparative clinical trials. Suppose there are k new treatments, named E1, E2
... Ek, with success probability θ1, θ2...θk, and the standard treatment is E0 with
success probability θ0. The outcomes are binary, either success or failure. The
designs are based on the hypothesis test:
H0 : θ0 = θ1 = ... = θk.
H1 : least favorite condition.
Here the least favorite condition is defined as
Theorem 1 (Least Favorable Condition (LFC)) Let θ = (θ0, θ1, ...θk), at least
one of Ej is acceptable, θ1 = ... = θk−1 = θ0+δ1 are not acceptable, only θk = θ0+δ2
is acceptable. This vector θ minimize the power 1− β(θ).
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In stage 1, the best treatment with highest success probability is selected and
compared with the standard treatment. In stage 2, this selected treatment is
further tested. During the two stages, early rejection is permitted, but no early
acceptance is permitted. This is a controlled test, so one group take the standard
treatment and the other groups take new treatments.
In stage 1, for each kind of treatment, we test n1 patients, so (k+1)n1 patients are
tested. xji is the number of success of treatment j in stage i, j = 0, 1, ...k, i = 1, 2.
Let a statistic T1 to show the difference in success probability between the best






(Zj1 − Z01) > y1 (2.4)
where xji is the number of success of treatment j in stage i, j = 0, 1, ...k, i = 1, 2,






T1 is standard normalized, and it is an monotone increasing function of the differ-
ence between best new treatment and standard treatment. If T1 > y1, we go on to
test the best treatment, say the vth treatment. Otherwise, even the best treatment
among k new treatments is no better than the standard treatment, obviously we
should stop test and declared none of the new treatment is promising. Suppose Ev
is selected as the best treatment in stage 1, in stage 2, additional n2 patients will
be tested for both E0 and Ev, so totally 2n2 patients are tested. After stage 2, we
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, T2 is also standard normalized. It includes the information of
two stages, giving weight pi. If T2 > y2, we accept the new treatment and declare
it is promising. Otherwise, reject it and conclude none of the new treatments is
better than the standard one.
The cutoff criteria, n1 and n2 are decided by minimizing the expect sample size in
the two stages under the constraints of size and power. The expected sample size




E(N | H0) + 1
2
E(N | LFC) (2.7)
Size is the probability that any Ev is chosen when H0 is hold. Power is the proba-
bility that Ek is chosen under least favorable condition (LFC)
The two-stage selection and testing designs for comparative clinical trials provide
us a way to deal with the problem if more than one new treatments in one test,
instead of testing them one by one, so the testing period is shortened. One disad-
vantage of this design is that the sample size is usually larger than previous Simon’s
design, because we need to test more patients at stage 1. The available patients
must be enough in order to get reasonable result.
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2.2 Bayesian Designs
Bayesian designs provide a good alternative to frequentist designs as they allow
for the incorporation of relative prior information and the presentation of the trial
results in a manner which is more intuitive and helpful.
2.2.1 Bayesian Two-stage Designs
Tan and Machin (2002) provide two-stage Bayesian designs which include two
stages in phase II clinical trail. It is an alternative method to Simon’s designs
reviewed in §2.1.1. We follow some of the notations in Simon’s designs, p1 repre-
sent the desirable probability, p0 represents the undesirable probability, r1 and r
are the cutoff boundaries of the two stages respectively, n1 and n2 are the number
of patients to be tested in two stages, and n = n1 + n2. But this design suppose
the true success probability of the new treatment is not an exact value pE, but a
Beta distribution θ, the prior distribution is θ0 = beta(a, b), and the posterior dis-
tribution θt = beta(at, bt), t=1,2, represents the posterior after stage 1 and stage 2.
There are two kinds of Bayesian two-stage designs, one is single threshold design,
the other one is dual threshold design. Both of them are based on the hypothesis
test:
H0: θ < p1
H1: θ ≥ p1
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For single threshold design, in stage 1, n1 patients are tested. After stage 1, we
detect whether the posterior probability satisfy
P (θ ≥ p1|x1, n1) ≥ λ1 (2.8)
where x1 is the number of success in stage one, λ1 is one of the constraints of this
design given in advance, which depends on the accurate requirement. In stage two,
additional n2 patients are tested, so the total number of two stages is n = n1 + n2.
After stage two, we test whether the posterior probability satisfy
P (θ ≥ p1|x1, x, n1, n2) ≥ λ2 (2.9)
where x is the number of success in two stages, λ2 is the other constraints of this
design, given in advance.
Let r1 be the minimum of x1 satisfying (2.8) and r is the minimum of x satisfying
(2.9). In the clinical trial, if the number of success in stage 1 is less than r1,
the treatment will be rejected by the end of stage 1, otherwise go on to stage
2. And if the total number of success in 2 stages is less than r, the treatment
will be announced nonpromising, otherwise, announced promising. Therefore, the
probability of the new treatment to be rejected after stage 1 is







B(a+ i, b+ n1 − i)
B(a, b)
(2.10)
where B(a, b) =
Γ(a)Γ(b)
Γ(a+ b)
. The cutoff boundaries of any two-stage design, r1 and
r, sample size n1 and n2 are all decided by minimizing the expected number of
patients EN = n1 + (1− PET )n2 under the constraints of λ1 and λ2.
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For the dual threshold design, the method is identical to the single threshold design
except that the stage 1 sample size and cutoff boundaries are not determined by
(2.8), instead they are determined by
P (θ ≤ p0|x1, n1) ≤ λ′1 (2.11)
where λ′1 is given in advance.
Compared with Simon’s two-stage frequentist designs, the two-stage Bayesian de-
signs have lower values of PET and larger values of sample size, but the sample size
could be decreased by applying more stringent λ1. The advantage of this design is
avoiding to control type I and type II errors, which need to be calculated in the
algorithm, instead giving values as constraints to the posterior probabilities.
2.2.2 Bayesian Sequential Designs
The Bayesian sequential design of Thall and Simon (1994) is an important sta-
tistical methodology in phase II clinical trials. The object of this approach is to
decide whether a new treatment, E, improves the success probability of a certain
disease by some given criterion, δ0, comparing with standard treatment. This is
a sequential single-armed design with early acceptance and early rejection. What
should be specify before the design are the prior distribution of new treatment,
distribution of standard treatment, a target improvement as criteria and range of
possible sample size. The design will lead to the decision boundaries, the distri-
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bution of sample size and other operating characters. The responses of patients
are binary. The standard treatment S and the new treatment E both have the
conjugated Beta distribution, θs = beta(as, bs) and θE = beta(aE, bE) respectively.
The designs based on the hypothesis test:
H0 : θE = θs
H1 : θE − θs ≥ δ0
Our criterion function to determine the trials decision cutoffs is the posterior prob-
ability
λ(x, n, δ0)




{1−Beta(p+ δ0; aE + x, bE + n− x)}beta(p, as, bs)dp (2.12)
Xn is the number of success out of n patients, n = 1, 2...nmax. Beta(aE + Xn, b +
n−Xn) is the posterior cumulative distribution function of E. The upper bound at
each stage to accept the new treatment is Un, which is the smallest integer x such
that λ(x, n, 0) ≥ pU and the lower bound to reject the new treatment is Ln, which
is the largest integer x such that λ(x, n, δ0) ≤ pL. pU and pL are the constraints
of the optimal design. Therefore, after each stage between nmin and nmax, we face
three choices of action accept, reject or continue, and before nmin we could only go
on.
This design minimizes the expected sample size under the control of probability to
accept and to reject the new treatment. The expected sample size is determined
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n(p+(n) + p−(n)) (2.13)
here p+(n) denotes the probability E to be accepted at stage n, and p−(n) denotes
the probability to be rejected at stage n.
Moreover, Thall and Simon (1994B) makes two extensions to previous designs. One
extension is the Bayesian guideline without early acceptance. Even though the new
treatment has good performance, we cannot accept it until the maximum sample
size is achieved. This method without upper bound is a safer strategy for patients.
Another extension is that adding an inner criteria to the existed guideline, if E is
unlikely to yield an high probability to either promising or non-promising by the
end of test, we will stop the test before the maximum sample size is achieved. If
at stage n, we have a very low probability to get an conclusion at the end using all
nmax patients, we should stop at sample size n to avoid wasting nmax− n patients.
Generally, the sequential Bayesian designs have less expected sample sizes than
the two-stage designs. But the prior distribution of the new treatment E plays
crucial roles to the posterior probability as well to the whole design. The effects of
prior-misspecifications in Bayesian sequential designs will be discussed in Chapter
4.
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2.3 Bayesian Decision Theoretic Designs
All the previously designs reviewed do not need to specify gain or cost functions.
Though they do not follow the strict decision framework, they are mathematically
reasonable and provide reliable methods. This part is a briefly review of some
designs using formal theoretic designs with specifying either gain or cost function.
Stallard (1998) applied the Bayesian decision theory to multi-stage designs to de-
termine the sample size of uncontrolled phase II clinical trials. Wang and Leung
(1998) and Leung and Wang (2001) provide fully sequential designs to screen series
of new treatments.
2.3.1 Multiple-stage Bayesian Decision Theoretic Designs
Stallard (1998) provided approach which uses the method of backward induction
to obtain group sequential designs by optimizing some specified gain function or
utility. Suppose that the outcomes are binary, failure and success, which is repre-
sented by Yj = 0/1, the new treatment has unknown success probability p, with
conjugate prior beta distribution pi0(p). Let sni = Y1 + ...+ Yni , for i = 1, 2...k. It
means we observe the number of success k times during the test, nk is the sample
size when we observe at kth time. If k = 1, this is a one stage Bayesian decision
theoretic design with fixed sample size; if k = 2, this is a two-stages Bayesian deci-
sion theory design; if k equals the total sample size, it is a fully sequential design.
CHAPTER 2. REVIEW OF FUNDAMENTAL DESIGNS 17
After each observation, we also faces three choices of action, a = {A,R,C}
A: stop and declare E promising
R: stop and declare E not promising
C: continue
In Nigel’s design, gain function is related to the true probability of success pE and
sample size nk and based on the assumption that cost of phase III is proportional
to sample size. The optimal action is defined as the action with largest expected
gain. Suppose we have a cost t for per patient, the gain function is:
GA(p, ni) = −nit (2.14)
GR(p, ni) = −nit−m+ l(ni)κ(p) (2.15)
where l is the reward of phase III study, which is depend on the speed of phase II
study, so l is a function of number of patients observed; κ(p) is the power of the
test, which is depend on p. The expected gain function is:




Ga(p, ni)pi(p | sni , ni)dp (2.17)
where pi is the posterior distribution of p given data. So expected gain function for
action A and P is:
gA(p, ni) = −nit
gR(p, ni) = −nit−m+ l(ni)E(κ(p) | sni , ni) (2.18)
CHAPTER 2. REVIEW OF FUNDAMENTAL DESIGNS 18
Because the gain of C at stage ni is equal to the gain continuing to next stage ni+1.
The gain function of C can be recursed.
2.3.2 Sequential Bayesian Decision Theoretic Designs
The previous designs reviewed can be one stage, two stage, multi-stage and even
sequential, which depends on the different value of k and the decision rule is based
on the expected gain. Wang and Leung (1998) provided other sequential Bayesian
decision theoretic designs with decision rule based on the cost functions instead
of gain functions. They are optimal designs screening a series of treatments in
order to identify the promising one with minimized expected sample size under the
restrictions of two error rates.
As the previous assumptions, both early rejection and early acceptance are permit-
ted and the outcomes are binary, Yi = 1 or 0 to represents success or failure of the
ith treatment. For each of the new treatment for test, the minimum and maximum
of sample size are nmin and nmax respectively. We suppose the θi is the probability
of success for ith treatment, with prior distribution pi0i, which is a conjugate prior
distribution, beta(a, b) and posterior piti. These designs are based on the hypothesis
test:
H0 : θi < θ
∗
H1 : θi ≥ θ∗
Because it is a sequential design, after the screening of each patient, we will face
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three choices, {A,R,C}, promising, non-promising and continue screening, which
is the same definition as the previous section. What decision to make depends on





C1P (θ < θ
∗ | pit) if accept,
C2P (θ ≥ θ∗ | pit) if reject.
(2.19)
where C1 and C2 as the cost of false positive and false negative. There are four
outcomes after each stage:
(1)Not reject H0 when θti < θ
∗, with probability p−−;
(2)Reject H0 when θti < θ
∗, with probability p+−;
(3)Not reject H0 when θti ≥ θ∗, with probability p−+; and
(4)Reject H0 when θti ≥ θ∗, with probability p++;
This design controlled two error rates, E1 and E2 , for a series of treatments.
E1 is defined as the test stop with a false positive treatment. E2 is defined as
any of the previous rejection is a false negative, which means if we stop at kth
treatment at time t and announce the kth treatment is promising, Ytk = 1 and
Yt1 = Yt2 = ... = Yt(k−1) = 0, but one of the rejections is false negative.













m−1 − (p−−)m−1(p+− + p++)
=
p−+
p+− + p++ + p−+
(2.21)
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Thus the expected minimum cost, named N(pi0;nmax), is as follows
N(pi0;nmax) = E(τ) +
∑
pit∈A





(P (pit)C2P (θ ≥ θ∗ | pit) +N(pi0;nmax)) (2.22)
which leads to
N(pi0;nmax) = Np + C1α1 + C2
α2
1− α2 (2.23)
where pA = p+− + p++,Np =
E(τ)
PA
, the expected number of patients required
to test before a promising treatment is identified, and Np is what the designs
minimized and E(τ) is the expected number of patients on each treatment. The
decision depends on N(pi0;nmax), which satisfy the recurrent relations of backward
induction:
When t = nnmax
N(anmax, bnmax , 0) = min{N(anmax , bnmax , nmax, 0, 2), N(anmax , bnmax , nmax, 0, 0)}
N(anmax , bnmax , 0, 2) = C1P (θ < θ
∗ | anmax , bnmax)
N(anmax , bnmax , 0, 0) = C2P (θ ≥ θ∗ | anmax , bnmax) +N(a, b, nmax)
when nmin < t < nmax
N(at, bt, nmax − t) = min
u
{N(at, bt, nmax − t, u)}, u = 0, 1, 2
N(at, bt, nmax − t, 0) = C2P (θ ≥ θ∗ | at, bt) +N(a, b, nmax)
N(at, bt, nmax − t, 1) = 1 + at
at + bt
N(at + 1, bt, nmax − t− 1)




N(at, bt + 1, nmax − t− 1)
N(at, bt, nmax − t, 2) = C1P (θ < θ∗ | at, bt)
when t = nmin
N(a, b, nmax − nmin + 1) = min{N(a, b, nmax, 1), N(a, b, nmax, 2)}
N(a, b, nmax − nmin + 1, 1) = 1 + a
a+ b




N(a, b+ 1,M − 1)
N(a, b, nmax, 2) = C1P (θ < θ
∗ | a, b)
where the u = 0, 1, 2 is equivalent to R,C,A, the prior distribution is Beta(a, b)
and the posterior distribution after t stages is Beta(at, bt).
The error rate α2 in this design is the probability of false rejections before iden-
tifying the first promising treatment, and it has two limits, one is the number of
rejected treatments is a random number, so it cannot be used as the error rate of
any particular trial, the other one is that it is only meaningful when the expected
number of rejected treatment is known. Therefore, it is motivated to control the
error rates for each of the treatment in stead of a series of treatments. In the
article Leung and Wang (2001), they designed to treat a series of new treatment
as identical, so that the design for a series of new treatments is just a series of
identical designs for testing individual treatment. And it requests the screening
without replacement, that is if a treatment is rejected as non-promising, it will not
be tested again. This requirement guarantees the series of treatments are identical,
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so that the identical designs could be applied to different treatments again and
again.
Now the error rate α2 is revised as the probability of rejecting promising treatments.






However, one of the shortcomings of Bayesian theoretic decision designs is the
difficulty in specifying gain or lost functions. Moreover, if the priors’ distributions
are misspecified, the designs will be affected as well. The sensitivity test of the
revised sequential Bayesian decision theoretic designs will be discussed in chapter
4.
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Chapter 3
Error Rates and Sample Size
In the previous chapter, we reviewed three kinds of fundamental statistical designs
in phase II study. One of the common points of those designs is that all the optimal
designs are under constraints of some error rates. Two-stage frequentist designs
use the type I error and type II error as the constraints to minimize either the
expected sample size or total sample size. Bayesian designs control the posterior
probability to minimize the expected sample size. And the sequential decision
theoretic frameworks use the probability of false positive and false negative as
the constraints for optimal designs. This chapter will illustrates the relationships
between the constraints of different designs and use an example to show the different
results by applying different constraints.
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3.1 Type I Error and Type II Error
In statistics, type I error is defined as the probability of rejecting the null hypoth-
esis, when the null hypothesis is true and type II error is defined as the probability
of not rejecting the null hypothesis, when the null hypothesis is not true. Fre-
quentist designs usually use type I error and type II error as the constraints for
optimization.
3.1.1 Optimal and Minimax Two-stage Designs
Simon (1989) two-stage frequentist design is based on the hypothesis test:
H0 : pE ≤ p0
H1 : pE ≥ p1
p0 is some undesirable value of success probability, p1 is some desirable value of
success probability and pE is the true success probability of new treatment. p0
and p1 are derived from the empirical study of standard treatment. The cutoff
values to reject a new treatment are r1 and r after the first stage, and second stages
respectively. For optimal designs, the expected sample size EN = n1+(1−PET )n2
should be minimized, where PET = B(r1, n1, pE). For Minimax designs, the total
sample size n is minimized. Both of them controls type I error (γ1) and type II
error (γ2) under some given accuracy requirement α and β. The probability
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reject the new treatment after two stages is
λ = B(r1, n1, pE) +
min[n1,r]∑
x=r1+1
b(x, n1, pE)B(r − x, n2, pE) (3.1)
Here reject null hypothesis is equivalent to accept the new treatment and not reject
null hypothesis is equivalent to reject the new treatment. Therefore, the type I and
type II error which are need to be controlled are:
γ1 = P (Reject H0 | pE = p0) = 1−[B(r1, n1, p0)+
min[n1,r]∑
x=r1+1
b(x, n1, p0)B(r−x, n2, p0)]
(3.2)
γ2 = P (Not reject H0 | pE = p1) = B(r1, n1, p1)+
min[n1,r]∑
x=r1+1
b(x, n1, p1)B(r−x, n2, p1)
(3.3)
3.1.2 Optimal Two-stage Design for More Than One New
Treatment
Thall, Simon and Ellenberg carried out the two-stage selection and testing designs
for comparative clinical trials. The designs are based on the hypothesis test:
H0 : θ0 = θ1 = ... = θk.
H1 : least favorite condition.
This design minimizes the expected total number of patients in two stages. The
expected sample size is subject to θ, so we calculate it under both H0 and least




E(N | H0) + 1
2
E(N | LFC) (3.4)
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And this optimization is under the constraints of two error rates, size (α) and power
(1−β). Size is the probability that any Ev is chosen when H0 is hold. Power is the
probability that Ek is chosen under least favorable condition. Therefore, to control
these two error rates are equivalent to control the type I and type II errors.
3.2 Probabilities of False Positive and False Neg-
ative
Wang and Leung (1998) and Leung and Wang (2001) provided two sequential
Bayesian decision theoretic designs with decision rule based on the cost functions.
Both designs are based on the hypothesis test:
H0 : θi < θ
∗
H1 : θi ≥ θ∗
The designs Wang and Leung (2001) assumes that there are infinite number of
new treatments, we test the sequence one by one; but Leung and Wang (2001)
shows that the design of Wang and Leung (1998) can be based on considering one
treatment only. But the error rates need to be controlled are different. And both
of the designs minimize the expected number of patients to identify the promising
one. But the optimizations are under the different error rates restrictions.
In the designs Wang and Leung (1998), the two error rates controlled are E1 and
E2. E1 is defined as the test stop with a false positive treatment and E2 is defined
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as any of the previous treatment is a false negative.













m−1 − (p−−)m−1(p+− + p++)
=
p−+
p+− + p++ + p−+
(3.6)
In the design of Leung and Wang (2001), the design controlled the error rate E1
and E ′2, which are the probability of false positive and probability of false negative,
respectively. E1 is the same as last designs, accepting a nonpromising treatment,
and E ′2 is defined as rejecting a promising treatment falsely.










Though the definition of E ′2 is different from E2, they are related in the relationship
α′2 =
α2p
1− (1− α2)(α1 + p) (3.9)
where p = p++ + p−+, for the Bayesian theoretic designs, we define p = P (θ ≥
θ∗|pi0), the prior probability of promising. Compared with the designs Wang and
Leung (1998), designs Leung and Wang (2001) used (α1, α
′
2) instead of (α1, α2) as
the constrictions of optimal designs to make the interpretation of error rates more
reasonable. The advantages in interpretation of α′2 can be shown by an example.
On one side, if in a trial, we reject 4 treatments before accepting a promising one,
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and α2=0.3, we cannot use it to make statements about the chance of false negative
errors in any of the four rejected treatments, because the number of rejection is a
random number. On the other side, by the relation between α′2 and α2, we known
α′2 = 0.084, the chance of a false negative for each of the four rejected treatment
is 0.084. Moreover, α2 = 0.3 is based on the average of 5.2 treatments rejected,
and the average is depend on both α1 and α2. If we vary α1, the average will
change too. But α′2 = 0.3, can only be interpreted as the error rates of rejection
for individual treatment rather than a series of treatments, and α1 will not change
with it.
Moreover, the two error rates in designs (2001) and the traditional type I and type
II error can be converted with each other. By definition, the type I error (γ1) and









First, we convert the probability of false positive (α1) and probability of false




(1− p)(1− α1 − α′2)
γ2 =
α′2(1− α1 − p)
p(1− α1 − α′2)
. (3.12)
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(1− p)γ1 + p(1− γ2)
α′2 =
pγ2
pγ2 + (1− p)(1− γ1)
. (3.13)
Therefore, there is no difference mathematically to control (α1, α
′
2) and (γ1, γ2), as
they can be converted from each other.
3.3 Posterior Probabilities
Bayesian designs provide a good alternative to frequentist designs as they allow
for the incorporation of relative prior information and the presentation of the trial
results in a manner which is more intuitive and helpful. And the constraints to
Bayesian designs are the posterior probabilities after each stage.
3.3.1 Bayesian Two-stage Designs
Tan and Machin (2002) provide two-stage Bayesian designs which include two
stages in phase II clinical trial. It is an alternative method to Simon’s designs
reviewed in §2.1.1.
The two-stage Bayesian designs are based on the hypothesis test:
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H0: θ < p1
H1: θ ≥ p1
There are two kinds of designs, one is single threshold and the other one is dual
threshold, due to different constraints of posterior probabilities after stage 1.
For single threshold designs, the two constraints of posterior probabilities are
P (θ ≥ p1|x1, n1) ≥ λ1 (3.14)
P (θ ≥ p1|x1, x, n1, n2) ≥ λ2 (3.15)
Formula (3.12) is to controll the posterior probability after first stage, when n1
patients were tested and x1 of them are success. Foumula (3.13) is to controll the
posterior probability after stage two, when n2 patients were tested in stage two
and x2 of them are success.
For dual threshold designs, the two constraints of posterior probabilities are
P (θ ≤ p0|x1, n1) ≤ λ′1 (3.16)
P (θ ≥ p1|x1, x, n1, n2) ≥ λ2 (3.17)
But both of the two kinds minimize the expected number of sample size
EN = n1 + (1− PET )n2 (3.18)
here PET is expressed in (2.10).
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3.3.2 Bayesian Sequential Designs
The Bayesian sequential designs by Thall and Simon (1994) are approaches to
decide whether a new treatment, E, improves the success probability of a certain
disease by a amount criterion, δ0, comparing with standard treatment. The designs
are based on the hypothesis test:
H0 : θE = θs
H1 : θE − θs ≥ δ0
The design minimizes the expected sample size by controlling the sequential pos-
terior probabilities (2.12) after each stage by dual thresholds.
λ(x, n, pis, piE, δ0)




{1−Beta(p+ δ0; aE + x, bE + n− x)}beta(p, as, bs)dp (3.19)
δ0 is the target improvement, Xn is the number of success of n patients, n =
1, 2...nmax. Beta(aE + Xn, b + n − Xn) is the posterior cumulative distribution
function of E. The dual thresholds are
λ(x, n, piS, piE, 0) ≥ pU (3.20)
λ(x, n, piS, piE, δ0) ≤ pL (3.21)
Let pL and pU be predetermined probabilities, pL usually takes small value such as
0.01 to 0.05, and pU usually takes large value such as 0.95 to 0.99.
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n(p+(n) + p−(n)) (3.22)
here p+(n) denotes the probability E to be accepted at stage n, and p−(n) denotes
the probability to be rejected at stage n.
3.4 Difference in Applying Different Constraints
The type I and type II error and probabilities of false positive and false negative
are two kinds of widely used error rates to constrain. But in the Bayesian designs,
the posterior probabilities are constrained for optimization. Now we take the two-
stage Bayesian design of Tan and Machin (2002), to see the different results under
different constraints.
Tan and Machin’s two-stage Bayesian designs control posterior probabilities, but
we also could calculate type I error and type II error, probabilities of false positive
and false negative. We shall follow the notation in Leung and Wang (2001) to













B(p1, a+ i+ j, b+ n− i− j)
B(a, b)
p++ = p+ − p+−









= P (θ ≤ x), θ is beta(a, b) distributed, and p = p++ + p−+ =
1− B(p1, a, b)
B(a, b)













B(a+ i+ j, b+ n− i− j)
B(a, b)
(3.24)
Therefore, we lead to probabilities of false positive and false negative:
α1 = P (θ < p1|Accept) = p+−
p+− + p++
(3.25)




and type I error (γ1) and type II error (γ2) are derived as

γ1 = P (Accept new treatment|θ < p1) = p+−
p+− + p−−
γ2 = P (Reject new treatment|θ ≥ p1) = p−+
p−+ + p++
. (3.27)
Now we come to whether different error rates controlled will lead to different design
parameters. We use an example to show the effect of different errors to the designs.
First, we follow the Tan and Machin (2002) two-stage Bayesian designs to control
the posterior probabilities, and evaluate the exact probability of false positive, false
negative, type II error and type II error. Then we change to control the probabilities
of false positive and false negative to illustrate the difference in results.
Table 3.1 and table 3.2 gives the type I error, type II error, probability of false
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positive and probability of false negative which are derived from single threshold
designs and dual threshold designs respectively. For the single threshold designs,
α1 and γ1 are small and reasonable controlled. But α
′
2 and γ2 are too large in some
cases. For the dual threshold designs, only γ2 values are too large. This implies the
dual threshold designs improve over the single threshold, however still not perfect.
Therefore, we change to control α1 and α
′
2 and minimize EN to find whether there
is any improvement. The results are give in Table 3.3, it shows that if we control
the probabilities of false positive and false negative, then type I error, type II error
and posterior probabilities are all successfully controlled.
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λ1 = 0.6, λ2 = 0.7
m(pi0) E(pi0) p1 r1/n1 r/n α1 α
′
2 γ1 γ2
0.10 0.37 0.25 2/4 6/17 0.024 0.392 0.025 0.387
0.40 7/14 16/35 0.037 0.166 0.020 0.276
0.50 11/20 25/44 0.039 0.101 0.013 0.264
0.75 27/33 43/53 0.063 0.035 0.003 0.409
0.90 35/36 47/49 0.116 0.01 0.001 0.688
0.30 0.43 0.40 4/7 13/28 0.031 0.267 0.023 0.326
0.50 9/15 21/37 0.033 0.161 0.016 0.290
0.75 23/28 39/48 0.058 0.055 0.006 0.386
0.90 31/32 42/44 0.132 0.017 0.002 0.610
0.50 0.50 0.50 5/9 17/30 0.039 0.188 0.031 0.225
0.75 19/23 34/42 0.058 0.080 0.01 0.354
0.90 26/27 37/38 0.100 0.033 0.002 0.614
0.75 0.58 0.75 13/16 28/34 0.050 0.122 0.016 0.313
0.90 20/21 31/32 0.116 0.054 0.008 0.495
λ1 = 0.6, λ2 = 0.8
0.10 0.37 0.25 2/4 16/51 0.009 0.382 0.009 0.377
0.10 0.40 7/14 36/78 0.011 0.172 0.006 0.293
0.10 0.50 11/20 49/88 0.017 0.099 0.005 0.262
0.10 0.75 27/33 71/88 0.028 0.037 0.001 0.430
0.10 0.90 35/36 64/67 0.067 0.010 0.000 0.715
0.30 0.43 0.25 2/4 13/42 0.009 0.463 0.016 0.329
0.30 0.40 4/7 32/70 0.010 0.266 0.008 0.330
0.30 0.50 9/15 45/81 0.013 0.161 0.006 0.292
0.30 0.75 23/28 65/81 0.030 0.056 0.003 0.394
0.30 0.90 31/32 58/61 0.079 0.018 0.001 0.639
0.50 0.50 0.25 2/4 10/32 0.008 0.544 0.025 0.284
0.50 0.50 5/9 41/73 0.012 0.188 0.010 0.229
0.50 0.75 19/23 60/75 0.029 0.081 0.004 0.363
0.50 0.90 26/27 53/55 0.055 0.033 0.001 0.627
0.75 0.58 0.75 13/16 53/66 0.027 0.116 0.008 0.298
0.90 20/21 46/48 0.067 0.055 0.004 0.506
Table 3.1: Design parameters and error probabilities using the Single Threshold Designs
with various values of (λ1, λ2). Here m(pi0) is the mode of the prior distribution.
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λ1 = 0.6, λ2 = 0.7
m(pi0) E(pi0) p0 p1 r1/n1 r/n α1 α
′
2 γ1 γ2
0.1 0.37 0.2 0.4 4/15 16/35 0.054 0.109 0.034 0.167
0.1 0.3 0.5 4/10 25/44 0.045 0.088 0.015 0.227
0.1 0.55 0.75 3/4 43/53 0.073 0.033 0.004 0.386
0.1 0.7 0.9 3/4 47/49 0.143 0.008 0.001 0.592
0.3 0.43 0.2 0.4 5/20 13/28 0.049 0.152 0.047 0.156
0.3 0.3 0.5 6/15 21/37 0.046 0.114 0.026 0.192
0.3 0.55 0.75 3/4 39/48 0.068 0.051 0.007 0.358
0.3 0.7 0.9 3/4 42/44 0.162 0.014 0.003 0.506
0.5 0.5 0.3 0.5 8/21 17/30 0.047 0.145 0.042 0.163
0.5 0.55 0.75 3/4 34/42 0.071 0.072 0.013 0.313
0.5 0.7 0.9 0/0 37/38 0.100 0.033 0.002 0.614
0.75 0.58 0.55 0.75 8/13 28/34 0.057 0.106 0.019 0.267
0.75 0.7 0.9 0/0 31/32 0.116 0.054 0.007 0.495
λ1 = 0.6, λ2 = 0.8
0.1 0.37 0.05 0.25 2/19 16/51 0.016 0.192 0.022 0.143
0.1 0.2 0.4 4/15 36/78 0.017 0.11 0.010 0.174
0.1 0.3 0.5 4/10 49/88 0.021 0.080 0.007 0.204
0.1 0.55 0.75 3/4 71/88 0.035 0.033 0.002 0.387
0.1 0.7 0.9 3/4 64/67 0.086 0.009 0.000 0.602
0.3 0.43 0.05 0.25 3/23 13/42 0.017 0.23 0.039 0.112
0.3 0.2 0.4 5/20 32/70 0.018 0.133 0.017 0.139
0.3 0.3 0.5 6/15 45/81 0.020 0.1 0.011 0.169
0.3 0.55 0.75 3/4 65/81 0.039 0.048 0.004 0.337
0.3 0.7 0.9 3/4 58/61 0.101 0.015 0.002 0.517
0.5 0.5 0.05 0.25 3/27 10/32 0.015 0.29 0.059 0.093
0.5 0.2 0.4 7/25 28/62 0.018 0.156 0.028 0.107
0.5 0.3 0.5 8/21 41/73 0.016 0.133 0.014 0.151
0.5 0.55 0.75 3/4 60/75 0.038 0.068 0.007 0.297
0.5 0.7 0.9 3/4 53/55 0.061 0.031 0.001 0.588
0.75 0.58 0.2 0.4 8/31 23/51 0.016 0.199 0.043 0.082
0.75 0.3 0.5 10/27 35/63 0.017 0.161 0.025 0.109
0.75 0.55 0.75 8/13 53/66 0.034 0.086 0.012 0.214
0.75 0.7 0.9 3/4 46/48 0.072 0.051 0.005 0.472
Table 3.2: Design parameters and error probabilities using the Dual Threshold Designs
with ² = 0.05 and various values of (λ1, λ2).
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m(pi0) p1 r1/n1 r/n α1 α
′
2 γ1 γ2 N¯
α1 ≤ 0.10, α′2 ≤ 0.10
0.1 0.25 2/12 7/30 0.095 0.099 0.161 0.057 25.8
0.1 0.5 4/8 12/21 0.099 0.100 0.034 0.254 12.9
0.1 0.75 2/2 12/12 0.088 0.069 0.001 0.833 3.9
0.1 0.9 4/4 34/34 0.100 0.012 0.000 0.851 6.5
0.3 0.5 6/13 13/24 0.098 0.099 0.060 0.158 18.4
0.3 0.75 3/3 14/15 0.082 0.094 0.004 0.691 5.0
0.3 0.9 4/4 31/31 0.100 0.023 0.001 0.810 7.2
0.5 0.5 5/13 13/25 0.096 0.100 0.096 0.100 21.1
0.5 0.75 2/2 20/24 0.098 0.099 0.015 0.445 8.9
0.5 0.9 4/4 28/28 0.099 0.040 0.001 0.759 8.0
0.75 0.75 6/8 21/26 0.097 0.099 0.035 0.244 15.4
0.75 0.9 5/5 24/24 0.100 0.073 0.004 0.676 8.7
α1 ≤ 0.05, α′2 ≤ 0.20
0.1 0.25 2/11 7/23 0.048 0.195 0.071 0.138 20.0
0.1 0.5 2/3 9/12 0.038 0.199 0.007 0.588 6.1
0.1 0.75 3/3 15/15 0.043 0.072 0.000 0.880 4.4
0.1 0.9 4/4 42/42 0.050 0.013 0.000 0.893 7.1
0.3 0.5 3/5 12/19 0.043 0.197 0.018 0.370 10.8
0.3 0.75 3/3 14/14 0.040 0.112 0.001 0.846 4.8
0.3 0.9 5/5 39/39 0.049 0.024 0.000 0.862 8.0
0.5 0.5 4/8 12/20 0.047 0.197 0.038 0.237 14.8
0.5 0.75 3/3 12/12 0.048 0.160 0.003 0.784 5.0
0.5 0.9 5/5 36/36 0.047 0.043 0.000 0.822 9.0
0.75 0.75 4/4 16/18 0.048 0.198 0.010 0.560 7.3
0.75 0.9 5/5 32/32 0.045 0.080 0.001 0.754 10.3
α1 ≤ 0.05, α′2 ≤ 0.10
0.1 0.25 3/19 14/54 0.050 0.100 0.080 0.063 46.1
0.1 0.5 4/9 22/38 0.044 0.100 0.014 0.260 21.5
0.1 0.75 3/3 15/15 0.043 0.072 0.000 0.880 4.4
0.1 0.9 4/4 42/42 0.050 0.013 0.000 0.893 7.1
0.3 0.5 4/9 27/50 0.049 0.099 0.028 0.163 30.6
0.3 0.75 2/2 17/18 0.045 0.100 0.002 0.742 6.0
0.3 0.9 5/5 39/39 0.049 0.024 0.000 0.862 8.0
0.5 0.5 6/15 26/49 0.050 0.100 0.047 0.106 37.2
0.5 0.75 4/5 28/33 0.047 0.097 0.007 0.440 13.5
0.5 0.9 5/5 36/36 0.047 0.043 0.000 0.822 9.0
0.75 0.75 6/8 40/50 0.050 0.097 0.017 0.243 25.3
0.75 0.9 5/5 32/32 0.045 0.080 0.001 0.754 10.3
Table 3.3: Design parameters and error probabilities using the Bayesian two-stage design
by minimizing the expected sample size under constraints of probability of false positive
and probability of false negative.
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Chapter 4
Effects of Prior-misspecifications
In Bayesian designs, the prior distribution of a new treatment plays crucial role in
deciding the cutoff boundaries and so that the expected sample size and two error
rates. But usually in practice, it is not easy to detect the prior distributions as
exactly as the truth. From that point of view, we are motivated to carry out statis-
tical research to find out how much the designs are affected by the misspecifications
of priors. If the misspecifications cause great changes to designs, those designs are
sensitive to priors misspecifications; if the misspecifications do not change the de-
signs’ parameters significantly, those designs are robust to prior-misspecifications.
In practice, we should pay more effort to specify the prior distributions if the de-
signs are sensitive, and we could save cost in specification of priors, if the designs
are robust.
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4.1 Effects of Priors-misspecifications on Bayesian
Sequential Designs
In this section, we carry out numerical analysis to test the effects of prior-misspecifications
in Bayesian sequential designs. This section consists three parts. In the first part,
we discuss the methodology of Bayesian sequential designs. In the second part,
we test the effects of prior means misspecifications, when the prior variances are
correctly specified. In the third part, we test the effects of prior variances misspec-
ifications, when the prior means are correctly specified.
4.1.1 Details of Bayesian Sequential Designs
4.1.1.1 Introduction
The Bayesian sequential designs are widely used to decide whether a new treatment,
E, improves the success probability of a certain disease by some given criterion,
δ0, comparing with the standard treatment. This is a sequential single-armed
design with early acceptance and early rejection. What should be specified before
Phase II trials are the prior distribution of new treatment, distribution of standard
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treatment, a target improvement as criteria and range of possible sample size. The
design will lead to the decision boundaries, the distribution of sample size and other
operating characters. The response of patients are binary. The standard treatment
S and the new treatment E both have the conjugated Beta distribution, θS and θE,
and pis and piE are the prior distributions’ density function of them.
pis = beta(as, bs) (4.1)
piE = beta(aE, bE) (4.2)
The means of priors is µS and µE respectively.
4.1.1.2 The Boundaries
Our criterion function to determine the trials decision cutoffs is the posterior prob-
ability. That is
λ(x, n, pis, piE, δ0)




{1−Beta(p+ δ0; aE + x, bE + n− x)}beta(p, as, bs)dp (4.3)
δ0 is the target improvement, Xn is the number of success out of n patients, n =
1, 2...nmax. Beta(p, aE + Xn, b + n − Xn) is the posterior cumulative distribution
function of E and beta(p, as, bs) is the probability density function of the standard
treatment.
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Let pL and pU be predetermined probabilities, pL usually takes small value such as
0.01 to 0.05, and pU usually takes large value such as 0.95 to 0.99.
The upper bound is
Un =the smallest integer x such that λ(x, n, piS, piE, 0) ≥ pU
and the lower bound is
Ln=the largest integer x such that λ(x, n, piS, piE, δ0) ≤ pL
Therefore, at each point of n from nmin to nmax, we face three choices of action:
A: If Xn ≥ Un, stop and declare E promising
P: If Xn ≤ Ln, stop and declare E not promising
C: If Ln < Xn < Un, continue
That means we accept E if it is highly likely to offer an improvement over S, and
reject E if it is very unlikely to provide an improvement of at least δ0 over the
standard treatment S. If Ln < Xmax < Un, this test is without conclusion. nmin
and nmax are the minimum sample size and maximum sample size. That implies
we accept E as promising or reject E as non-promising at least after testing nmin
patients and the overall design will test no more than nmax patients.
The upper bound and lower bound are iterative by S-plus in the following way. let
n variate in [nmin, nmax], for every fixed n, we can find the unique Ln and Un to
satisfy λ(x, n, piS, piE, 0) ≥ pU and λ(x, n, piS, piE, δ0) ≤ pL. This sequence of upper
and lower bounds will be used as guideline in real experiments.
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4.1.1.3 Error Rates
The optimal design is constrained by the posterior probabilities after each stage.
The design efficiency is described by the probability to reject and accept a new
treatment given success probability of the new treatment E. Suppose the true
success probability of E is pE, p+ denotes the probability that E is accepted, and
p− denotes the probability E is rejected. If the design is good, we will have high
p+ and low p− as a result, when pE is high; or we will have low p+ and high p−,













P [Xn ≥ Un]. n = nmin





P [Xn ≤ Ln]. n = nmin
(1− pE)P [Xn−1 = Ln−1 − 1, An−2]I[Ln = Ln−1 + 1] n > nmin
(4.7)
P [N = n] =


p+(n) + p−(n). n < nmax,
P [An−1], n = nmax
(4.8)
p+(n) denotes the probability E to be accepted at stage n, and p−(n) denotes the
probability to be rejected at stage n. Here there is a set Cn = {Ln + 1, ...Un − 1},
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it is the set of Xn without conclusion. An = {Xi ∈ Ci, nmin ≤ i ≤ nmax}, it is the
set of Xn, that all the previous stages before n
th stage( including nth stage ) are all
without conclusion. Therefore the expected sample size is EN =
nmax∑
n=nmin
nP [N = n].
The cutoff boundaries are decided by minimizing EN under the constraints of dual
thresholds.
4.1.1.4 Prior-misspecifications
There are two kinds of prior-misspecifications, one is the misspecifications of prior
means when the prior variances are correctly specified, and the other one is the
misspecifications of prior variances when the prior means are correctly specified.
When the priors are misspecified as either kind, the design will lead to different
boundaries of cutoffs, expected number of patients, probability of acceptance and
probability of rejection. The effects of prior-misspecifications are represented by
the expected sample size (EN), probability of rejection (p−), acceptance (p+) and
no conclusion after the maximum sample size reached (1− p− − p+).
For example, suppose the distribution of standard treatment is beta(8.15, 32.6) with
mean 0.2 and variance 0.0038, the target improvement of new treatment is 0.15, the
success probability of a new treatment pE is 0.35, a promising one, the true prior
of a new treatment is beta(1.43, 2.12), with mean 0.35 and variance 0.05, pU=0.95,
pL=0.05, nmin = 10 and nmax = 40. When the prior is correctly specified, the
expected sample size is 22.3402, probability to be rejected and accepted is 0.082 and
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0.6641 respectively. But if the prior is misspecified as beta(0.43, 1.60) with mean 0.2,
a poor treatment, and variance 0.05, the expected sample size 21.3786, probability
to be rejected and accepted is 0.1871 and 0.5825 respectively. Moreover, if the prior
mean is misspecified as beta(1.84, 1.84) with mean 0.5, a very successful treatment,
and variance 0.05, the expected sample size 20.7853, probability to be rejected and
accepted is 0.0535 and 0.7374 respectively. The changes are caused by different
boundaries decided by different prior distributions. The different boundaries are
plots in the figure 4.1.
4.1.2 Effects of Prior Means Misspecifications
In this part, we test the effects of prior means misspecifications on expected sample
size (EN), probability to reject (p−) and accept (p+), under different values of prior
variances and success probability of new treatments. We suppose the standard
treatment of some kind of disease has a beta distribution, beta(8.15, 32.6) with mean
0.2 and variance 0.003832. There is a new treatment and we want a promising new
treatment improves the standard treatment by 0.15. Considering the time and cost,
the maximum and minimum patients we can test are 10 and 40 respectively. The
cutoff boundaries are decided by the posterior probability, with pU=0.95, pL=0.05.
We suppose there are three possible values of prior variance 0.05, 0.1 and 0.15. If
the variance is 0.05, it is a very informative prior with very low variance; if the
variance is 0.15, it is a relatively disperse prior with large variance. And there
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Figure 4.1: Plots of True Boundaries and Misspecified Boundaries. True boundaries are
based on beta(1.43, 2.12); Misspecified boundaries 1 are based on beta(0.43, 1.60); and
Misspecified boundaries 2 are based on beta(1.84, 1.84).
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Prior aE bE Mean Variance
1 0.4 1.6 0.2 0.05
2 0.75 1.99 0.275 0.05
3 1.43 2.12 0.35 0.05
4 1.52 2.06 0.425 0.05
5 1.84 1.84 0.5 0.05
6 0.12 0.48 0.2 0.1
7 0.27 0.72 0.275 0.1
8 0.45 0.83 0.35 0.1
9 0.61 0.83 0.425 0.1
10 0.75 0.75 0.5 0.1
11 0.01 0.05 0.2 0.15
12 0.09 0.24 0.275 0.15
13 0.18 0.34 0.35 0.15
14 0.27 0.36 0.425 0.15
15 0.33 0.33 0.5 0.15
Table 4.1: Prior distribution beta(aE , bE) applied in this chapter.
are three possible success probabilities of new treatment, if pE=0.2, it is a very
poor treatment without any improvement to the standard treatment; if pE=0.35,
it is a promising one; if pE=0.5, it is a very successful treatment, with success
probability exceeding the promising level. Then we suppose 5 different prior means
to each value of prior variance, all the possible priors and corresponding means and
variances are listed in the Table 4.1.
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4.1.2.1 Effects of Prior Means Misspecifications on Expected Number of
Patients
In Bayesian sequential designs, the expected number of patients is minimized, un-
der the constraints of posterior probabilities. Whether EN changes much with the
prior misspecification is an important criterion to decide the robustness of the de-
signs.
In figure 4.2, we find if the new treatment is really very successful, for all prior cor-
rect or misspecified, we need less patients to be tested before accept it as promising
one. In the plots, when pE=0.5, which is a treatment with very high success level,
then those EN are below 14.08 for all priors correct or misspecified, and if the new
treatment has pE=0.2 or 0.35, EN are all above 18. In most of the cases, small
variance leads to smaller EN only when the prior mean is correctly specified, but
large variance leads to smaller EN when the prior mean is misspecified. The differ-
ences are not significant when prior is correct, but they are significant when prior
is misspecified. In figure 4.2, if pE=0.2, EN is 17.9239 using prior variance 0.05,
and EN is 19.1662 using prior variance 0.15, the difference is only 1.2423. And
if pE=0.5, EN is 13.7547 using prior variance 0.05, and EN is 13.4428 using prior
variance 0.15, the difference is as small as 0.3119. But if pE = 0.35, even the prior
is correct, small variance 0.05 leads to maximum EN.
And small variance priors are sensible to the misspecifications of prior means, but
large variance are robust to it. In figure 4.2, when the prior variance is 0.05, the
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Figure 4.2: Plots of Expected Number of Patients. The top plot is based on pE = 0.2,
the middle plot is based on pE = 0.35, and the bottom plot is based on pE = 0.5.
Prior=1, 2, 3, 4, 5 represents the prior variance applied is 0.2, 0.275, 0.35, 0.425, 0.5.
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variation is great when the prior means are specified. When the prior variance is
large, 0.15, the lines of EN like straight horizontal lines, it implies the changes in
EN caused by the misspecifications of prior means are relatively much less.
Moreover, the effects of misspecifications of prior means on EN decrease with pE
increases. When pE=0.2, if we use the true mean 0.2, variance 0.05, EN is 17.9239,
but when we misspecified the prior mean, EN become to vary in a range 12.7641.
When pE=0.35, if the prior mean is misspecified as extreme ones, such as 0.2 or
0.5, very poor treatment or very promising treatment, the expected sample sizes
are lower than that of the true one. But if the prior mean is misspecified as the one
which is not quite different from the true one, the expected sample size is higher
than the true one. The range of variation decreases to about 2. When pE=0.5, the
more misspecified prior mean, the higher EN. But the range of variation is only
1.4849.
As a conclusion, only when the prior means are correctly given, the Bayesian se-
quential designs with smallest prior variance could lead to the smallest expected
sample size, while if the prior variance is a larger one, we will have more chance to
get a smaller expected sample size and the variation of the expected sample size
is less than using the small variance. This is a good point for the design, EN is
robust for disperse priors instead of requiring informative priors. We need not test
too many patients in the phase II study, we just pay more attention to the how to
detect the means instead of decreasing variance. In a word, the expected number
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of patients in Bayesian sequential designs are quite robust when the prior variance
is large or the true success probabilities of the new treatments are really high.
4.1.2.2 Effects of Prior Means Misspecifications on Probability of Rejec-
tion
p− is the probability to reject a new treatment in the Bayesian sequential design.
If p− changes greatly when we misspecified the priors mean, the design will lose
power to reject nonpromising treatments or accepting promising treatments. Obvi-
ously, whether p− varies too much with prior mean misspecification is an important
criterion to decide the robustness of the Bayesian sequential designs.
In figure 4.3, if the true success probability of new treatment is higher, the prob-
ability to reject the new treatment as a nonpromising one p− is lower and if pE is
lower, p− is higher. This could be seen from the plots, if pE=0.2, a nonpromising
treatment, the probability to be rejected at least 0.4; if pE=0.35, a promising one,
p− are between 0.05 to 0.2; if pE=0.5, p− are all below 0.016. And small prior vari-
ance designs reject nonpromising treatments with highest probability and accept
promising treatments with lowest probability, only if the prior mean is correctly
specified. But the difference is not significant. For example, in figure 4.3, when
pE=0.2, if the prior variance is 0.15, mean is correct, p− =0.7708, which is only
0.07 lower than the p− of prior variance 0.05. On the contrary, large prior variance
designs are robust to the prior means misspecifications. If true prior variance is
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Figure 4.3: Plots of Probability of Rejection. The top plot is based on pE = 0.2, the
middle plot is based on pE = 0.35, and the bottom plot is based on pE = 0.5. Prior=1,
2, 3, 4, 5 represents the prior variance applied is 0.2, 0.275, 0.35, 0.425, 0.5.
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relatively large, but still acceptable, such as 0.15, true prior mean 0.2, if pE is 0.2,
the new treatment will be rejected with a probability, p−=0.7708, though it is not
as high as that of prior variance 0.05, 0.8408, but the design still works well. In
figure 4.3, the probabilities of rejection based on prior variance 0.15 are smooth
horizontal lines.
Moreover, the effects of prior means misspecifications decrease with the increase of
true success probability of the new treatment. For example, when pE=0.2, prior
variance is 0.05, if the prior mean is correctly specified, p−= 0.8408, but if it is
misspecified as a better treatment with mean 0.35, variance 0.05, p− is 0.4735.
Therefore, the misspecification makes the design lose much power. If pE=0.35 and
0.5, all p− for different prior means correct or misspecified are all under 0.2, even
there are changes, the changes cannot change the conclusion and the design is still
very powerful.
In addition, when the prior mean is misspecified as a higher one, p− decreases;
when the prior mean is misspecified as a lower one, p− increases. This result is
because that higher prior mean will higher to make the posterior probability of
success hit the target improvement, while lower prior mean will make the posterior
of success probability lower.
In a word, the probability of rejection in Bayesian sequential designs are robust,
when the prior variance is larger or the true success probability of new treatments
are really high.
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4.1.2.3 Effects of Prior Means Misspecifications on Probability of Ac-
ceptance
p+ is the probability to accept a new treatment in the Bayesian sequential design.
If p+ changes greatly when we misspecified the priors mean, the design will lose
power to accept promising treatments or accept nonpromising treatments mistak-
enly. Obviously, whether p− varies too much with prior mean misspecification is
an important criterion to decide the robustness of the Bayesian sequential designs.
In figure 4.4, if the true success probability of new treatment pE is higher, the
probability to be accepted as a promising one p+ is higher and if pE is lower, p+ is
lower. This could be seen from the plots, if pE=0.2, a nonpromising treatment, p+
is less than 0.13; if pE=0.35, p+ is always between 0.58 and 0.76; if pE=0.5, p+ is
above 0.95. And generally speaking, the effect of misspecification of prior mean on
p+ is not serious for this setting of design. Since when pE=0.2, the new treatment
is quite poor, no improvement compared with standard treatment, no matter the
true prior mean or misspecified mean is used, the probability to be accepted as a
promising treatment is under 0.12 for all prior variances. When pE=0.5, the new
treatment is better than promising level, all p+ is above 0.9697 for all prior variance
either true prior mean or misspecified prior mean. But we still can observe some
effect of the misspecification.
In figure 4.4, we find that if the prior variance is small, the prior mean is correctly
specified, p+ is always the highest one for promising treatment; and p+ is always
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Figure 4.4: Plots of Probability of Acceptance. The top plot is based on pE = 0.2, the
middle plot is based on pE = 0.35, and the bottom plot is based on pE = 0.5. Prior=1,
2, 3, 4, 5 represents the prior variance applied is 0.2, 0.275, 0.35, 0.425, 0.5.
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the lowest for nonpromising treatment if prior variance is smallest. This mean
when using the correct prior mean, the less prior variance, the design perfumes
better. But if the variance is smaller the variation caused by misspecification is
larger. Therefore, small prior variance only perfumes well when the prior mean
is true. But it is not resistant to misspecification. On the contrary, if the prior
variance is relatively larger, like 0.15, p+ become much more stable, for all prior
mean, the changes are quite small.
4.1.2.4 Effects of Priors Means Misspecifications on Probability of No
Conclusion
The probability of no conclusion after the maximum sample size is abstained by
1 − p− − p+. It is also an important criterion to criticize the Bayesian sequential
designs. If a design with high probability of no conclusion, the design will not be
practicable, since time and financial considerations. But sometime, this probability
may loss power. When both p− and p+ are around 0.5, therefore, 1−p−−p+ could
be very small. However, we still cannot reject or accept with confidence. In most
of the cases, the probability of no conclusion can provide valuable information.
From figure 4.5, we could find obviously that for all means, correct or misspecified,
and all variances, the probability of no conclusion decreases with the probability
of success probability. Only if prior mean is correct, small prior variance can lead
to small probability of no conclusion. But the variation caused by misspecification
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of prior mean has more effect on no conclusion probability of small variance than
on that of large variance.
4.1.3 Effects of Prior Variances Misspecifications
In this part, we discuss the effects of prior variances misspecifications. We let the
mean always be the same as the true success probability of new treatment, pE,
but the variance varies from 0.05, 0.075, 0.1, 0.125 and 0.15. And we still use
EN, p−, p+ and 1 − p− − p+ as the criteria to show the sensitivity of Bayesian
sequential designs. The results are listed in tables and figures. In the plot of EN vs
prior variance, for all variance level from 0.05 to 0.15, when success probability of
treatment pE is extreme low or high, pE=0.2 or 0.5, the expected sample sizes are
usually smaller. When pE=0.5, the highest, the expected sample sizes are lowest
for all variances; when pE=0.35, the new treatment is neither extreme promising
nor nonpromising, the sample sizes are highest.
In the plot of p− vs prior variance, probability to reject the new treatment p−
decreases with the increase of success probability of the new treatment pE. If the
success probability pE is low 0.2, p− is more than 77%; if pE is 0.35, p− is less than
16.1% and if pE is 0.5, p− is much less, even close to 0. On the contrary, in the
plot of p+ vs prior variance, probability to accept the new treatment p+ increases
with the increase of success probability of the new treatment pE.
More important is that from the figure 4.6, we could find that when the prior mean
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Figure 4.5: Plots of Probability of No Conclusion. The top plot is based on pE = 0.2, the
middle plot is based on pE = 0.35, and the bottom plot is based on pE = 0.5. Prior=1,
2, 3, 4, 5 represents the prior variance applied is 0.2, 0.275, 0.35, 0.425, 0.5.
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is correct, whatever the variances are large or small, the difference in expected
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Figure 4.6: Plots of EN, p−, p+ and 1− p− − p+ vs Prior Variance.
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value of pE, the changes in EN, which are caused by misspecification of prior
variance, are very limited. Only when pE =0.2 and 0.35, if the variance increase
from 0.05 to 0.075, expected sample size of treatment with success probability 0.2
decrease by 1.24, while that of treatment with success probability 0.35 decrease
by 1.71, both changes are less than 2, which is small compared with the value of
expected sample size. In the plots of p−, p+ and 1 − p− − p+ vs prior variance,
there is nearly no change in probability to reject, accept or no conclusion after test,
when given different prior variances for all level of pE. As a result, the effects of
prior variances misspecifications are not significant on Bayesian sequential designs,
when the prior means are correctly specified.
From the above numerical analysis, we could come to the following conclusions.
First, if the success probability of the new treatment pE is very high or very low,
we could expect to use less sample size to accept or reject the new treatment. In
addition, higher pE makes the probability of acceptance higher and lower pE makes
the probability of rejection higher.
Second, when we apply the correct prior means to Bayesian sequential designs, the
effect of misspecification of variance is very limited.
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4.2 Effects of Prior-misspecifications on Sequen-
tial Bayesian Decision Theoretic Designs
In this section, we carry out numerical analysis to test the effects on prior-misspecifications
of sequential Bayesian decision theoretic designs. This section consist three parts,
in the first part, we discuss the methodology of Bayesian theoretic designs; in the
second part, we test the effects of prior means misspecifications and in the third
part, we test the effects of prior variances misspecifications.
4.2.1 Details of Sequential Bayesian Decision Theoretic De-
signs
4.2.1.1 Introduction
Leung and Wang (2001) provided the sequential Bayesian decision theoretic designs
with decision rule based on the cost function. It is an optimal design screening a
series of treatments in order to identify the promising one with minimized sample
size and under the restriction to two error rates.
As the previous assumptions, both early rejection and early acceptance are per-
mitted between the minimum and maximum sample size are nmin and nmax respec-
tively. The outcome of each patient is binary, success or failure. We suppose the θi
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is the probability of success for ith treatment, with prior distribution pi0i, which is a
conjugate distributed, beta(a, b) and posterior distribution is piti, beta(at, bt) at t
th
stage, nmin ≤ t ≤ nmax. If the treatment with posterior probability larger or equal
to some given criteria θ∗, it is announced promising or positive; if the treatment
with posterior probability less than θ∗, it is announced non-promising or negative.
4.2.1.2 Cost Function
Because it is a sequential design, after the screening of each patient between nmin
and nmax-1, we will face three possible conclusions for the treatment, {A,R,C},
promising, non-promising and continue screening. And when the nmax is reached,
we have only two choices, either announce promising or nonpromising. What de-






C1P (θ < θ
∗ | pit) if accept,
C2P (θ ≥ θ∗ | pit) if reject.
(4.9)
where C1 and C1 as the cost of false positive (accept a non-promising treatment)
and false negative (reject a promising treatment)
When the cost to reject or accept is less than the cost to continue, we test the
hypothesis H0 : θti < θ
∗ vs. H1 : θti ≥ θ∗, therefore, there are four possible
decisions and probabilities:
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(1)Not reject H0 when θi < θ
∗, with probability p−−;
(2)Reject H0 when θi < θ
∗, with probability p+−;
(3)Not reject H0 when θi ≥ θ∗, with probability p−+; and
(4)Reject H0 when θi ≥ θ∗, with probability p++;
Each decision is made to minimize the expected cost function, which is calculated
by the recurrent algorithm.
N(a, b, nmax) = E(τ) +
∑
pit∈A




C2P (θ ≥ θ∗|pit)
= E(τ) + C1α1 + C2α
′
2
here N(a, b, nmax) mean at the beginning, prior distribution is beta(a, b) and the
treatment has as more as nmax patients could be tested in the following stages. At
each stage the cost are:
If t = nmax
N(anmax , bnmax , 0) = min{N(anmax , bnmax , nmax, 0, 2),
N(anmax , bnmax , nmax, 0, 0)}
N(anmax , bnmax , 0, 2) = C1P (θ < θ
∗ | anmax , bnmax)
N(anmax , bnmax , 0, 0) = C2P (θ ≥ θ∗ | anmax , bnmax)
If nmin ≤ t < nmax
N(at, bt, nmax − t) = min
u
{N(at, bt, nmax − t, u)} u = 0, 1, 2
N(at, bt, nmax − t, 0) = C2P (θ ≥ θ∗ | at, bt)
N(at, bt, nmax − t, 1) = 1 + at
at + bt
N(at + 1, bt, nmax − t− 1)




N(at, bt + 1, nmax − t− 1)
N(at, bt, nmax − t, 2) = C1P (θ < θ∗ | at, bt)
If t < nmin








N(a, b+ 1, nmax − 1)
If t = 0, the prior distribution is beta(a, b). In the recurrent relationship, N(at, bt, nmax−
t, i), i = 0, 1, 2, represents the cost to reject, continue or accept the new treatment
stage t respectively, the posterior distribution is beta(at, bt), and maximum nmax−t
more patients could be available to go on the test. And during the recurrent pro-
cedure, the design could neither reject nor accept any new treatment, until nmin
patients are tested. But when nmax patients are tested, the design must either
reject or accept the new treatment. One advantage of sequential Bayesian decision
theoretic designs is that when we decide the cutoff boundaries, we request if the
maximum sample size is reached, a conclusion must be made, so the probability of
no conclusion after a clinical trial is 0.
E(τ) is the expected number of patients on each treatment and Np =
E(τ)
p++ + p+−
is the expected number of patients to test in order to find a promising one. Np is
minimized in the sequential Bayesian decision theoretic designs under constraints
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of two error rates as follows.
4.2.1.3 Error Rates
For Bayesian method, we define p = P (θi ≥ θ∗) = p++ + p−+, which is the 1 minus
cumulative distribution of beta(a,b). From the recurrent relationship, we could
obtain p+− and p−+ directly, and then use the relationship p−−+p−++p+−+p++ = 1
to calculate p−−. The optimized cost function are controlled by two error rates,
(α1, α
′
2). α1 is the probability to accept a nonpromising treatment, false positive









For different value of prior, we try to give different value of C1 and C2 to minimize
Np under constraints of (α1, α2), and at the same time the decision boundaries are
determined. The proper combinations of C1 and C2 are listed in the table according
to different value of (α1, α
′
2), which are listed in Table 4.2.
4.2.1.4 Prior-misspecifications
Like the prior-misspecifications in Bayesian sequential designs, there are also two
kinds of prior-misspecifications in sequential Bayesian theoretic designs, one is the
misspecifications of prior means when the prior variances are correctly specified,
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1 0.40 1.60 0.200 0.050 60 75 60 75 10 15 10 15
2 0.75 1.99 0.275 0.050 70 85 70 85 20 25 10 15
3 1.43 2.12 0.350 0.050 50 55 50 55 30 45 30 45
4 1.52 2.06 0.425 0.050 40 55 20 25 30 75 30 75
5 1.84 1.84 0.500 0.050 30 55 10 15 20 85 20 85
6 0.23 0.91 0.200 0.075 30 45 30 45 20 75 20 75
7 0.46 1.20 0.275 0.075 10 15 10 15 20 55 20 55
8 0.70 1.30 0.350 0.075 30 45 30 45 20 55 20 55
9 0.96 1.30 0.425 0.075 20 35 20 35 20 65 20 65
10 1.17 1.17 0.500 0.075 20 45 20 45 10 45 10 45
11 0.12 0.48 0.200 0.100 20 85 20 85 10 75 10 75
12 0.27 0.72 0.275 0.100 20 55 20 55 10 35 10 35
13 0.45 0.83 0.350 0.100 20 55 20 55 20 85 20 85
14 0.61 0.83 0.425 0.100 20 55 20 55 10 55 10 55
15 0.75 0.75 0.500 0.100 10 35 10 45 10 55 10 55
16 0.06 0.22 0.200 0.125 10 75 10 75 10 75 10 75
17 0.16 0.43 0.275 0.125 10 25 10 25 10 95 10 95
18 0.29 0.53 0.350 0.125 20 65 20 65 10 95 10 95
19 0.41 0.55 0.425 0.125 20 75 20 75 10 85 10 85
20 0.50 0.50 0.500 0.125 10 55 10 55 10 75 10 75
21 0.01 0.05 0.200 0.150 10 85 10 75 10 75 10 75
22 0.09 0.24 0.275 0.150 10 75 10 75 10 75 10 75
23 0.18 0.34 0.350 0.150 10 65 10 65 10 95 10 95
24 0.27 0.36 0.425 0.150 10 85 10 85 10 85 10 85
25 0.33 0.33 0.500 0.150 10 85 10 85 10 95 10 95
Table 4.2: Prior beta distributions and corresponding C1 and C2. * is based on (α1, α2) =
(0.15, 0.15), † is based on (α1, α2) = (0.15, 0.2), ‡ is based on (α1, α2) = (0.2, 0.15), § is
based on (α1, α2) = (0.2, 0.2).
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and the other one is the misspecifications of prior variances when the prior means
are correctly specified. When the priors are misspecified as either kind, the design
will lead to a different cutoffs, expected number of patients to find a promising
treatment, probability of false positive and probability of false negative. The effects
of prior-misspecifications in sequential Bayesian theoretic designs are represented
by the expected number of patients to find a promising treatment (Np), probability
of false positive (α1) and probability of false negative (α
′
2).
For example, suppose a new treatment has the true prior beta(1.43, 2.12) with
mean 0.35 and variance 0.05, the target promising level is 0.35, the constraints
of two error rates are (α1, α
′
2) = (0.15, 0.15). If the prior is correctly specified,
we will use the design with C1=50 and C2=55, and by the recurrent relationship,
we could get the true boundaries, and Np is 23.48, probability of false positive,
α1, is 0.1465, and probability of false negative, α
′
2, is 0.1149. But if the prior is
misspecified as a higher prior mean 0.5 and correct variance 0.05, beta(1.84, 1.84),
Np decrease to 16.3391, α1 increase to 0.2014, and α
′
2 decrease to 0.0892. If the
prior is misspecified as a lower prior mean 0.2 and the prior variance is correct
0.05, beta(0.4, 1.6), Np increase to 25.4082, α1 decrease to 0.1237, and α
′
2 increase
to 0.1214. The changes are cause by the shift of the boundaries, which are plotted
in figure 4.7. In the upper plot, when the prior mean is misspecified as a higher
one, the boundaries shifts down, while when the prior mean is misspecified as
lower one, the upper bound of misspecified one is obviously higher than the true
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one. The misspecifications of prior variances is similar to this misspecifications of
prior means.
4.2.2 Effects of Prior Means Misspecifications
In this part, we test the effects of prior means misspecifications on expected number
of patients to test to find a promising treatment (Np), the probability of false
positive (α1) and the probability of false negative (α
′
2). We suppose the prior
variances are always correctly specified. There are five values of possible means,
0.2, 0.275, 0.35, 0.425 and 0.5, from nonpromising to promising and till exceeding
promising. We let the variance vary in 3 values, 0.05 a very low one, 0.1 a higher
one, and 0.15, the highest one. And there are 4 combinations of the error rates
as constrains for optimal design, (α1, α
′
2)= (0.15,0.15), (0.15,0.2), (0.2, 0.15) and
(0.2,0.2). The target success probability of a promising treatment is θ∗ =0.35. The
minimum and maximum number of patients to be tested for one treatment is 10
and 40 respectively.
4.2.2.1 Effects of Prior Means Misspecifications on Expected Number of
Patients
The sequential Bayesian theoretic designs minimized the expected number of pa-
tients to be tested in order to find a promising treatment (Np), under the constraints
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Figure 4.7: Plots of True Boundaries and Misspecified Boundaries. True Boundaries
are based on beta(1.43, 2.12); Misspecified boundaries 1 are based on beta(1.84, 1.84);
Misspecified boundaries 2 are based on beta(0.43, 1.60).
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of two error rates. Whether Np changes much with the prior-misspecification is an
important criterion to decide the robustness of the designs. From figure 4.8 to 4.10,
we find that when we give a higher error rate permitted, the number of patients
needed to find a promising treatment is less than the that under stringent error
rates. The decrease in Np is about 1 to 2, when we increase (α1, α
′
2) = (0.15, 0.15)
to (α1, α
′
2) = (0.2, 0.2). And we also find that if we just increase or decrease α1
or α2, Np nearly has no change, only when both the two error rate change, Np
will change. But overall, the change is only between 1 and 2, so the design will
not be greatly affected if increase the error rates from (α1, α
′
2) = (0.15, 0.15) to
(α1, α
′
2) = (0.2, 0.2). And the variation of Np caused by misspecification of prior
mean does not change among different combinations of error rates.
From the three figures, we find no matter the prior mean is correctly specified
or misspecified, if the true prior mean is higher, Np is lower. For (α1, α
′
2) =
(0.15, 0.15), if true prior mean is 0.2, a nonpromising treatment, for all prior vari-
ance, Np is from 35 to 50; if true prior mean is 0.35, a promising one, for all prior
variance, Np is from 16 to 26; if true prior mean is 0.5, a very successful one, for
all prior variance, Np is from 13 to 17. For (α1, α
′
2) = (0.2, 0.2), if true prior mean
is 0.2 for all prior variance, Np is from 28 to 47; if true prior mean is 0.35, Np is
from 18 to 23; if true prior mean is 0.5, Np is from 12 to 16. It implies that higher
true means are, the lower the expected number of patients to be tested.
We also find that, medium prior variance 0.1 designs lead to low Np in most of the
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Figure 4.8: Plots of Np When Correct Prior Mean is 0.2. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20), (0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior mean
applied is 0.2, 0.275, 0.35, 0.425, 0.5.
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Figure 4.9: Plots of Np When Correct Prior Mean is 0.35. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior mean
applied is 0.2, 0.275, 0.35, 0.425, 0.5.



































































Scatterplot of Np vs Group
Figure 4.10: Plots of Np When Correct Prior Mean is 0.5. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior mean
applied is 0.2, 0.275, 0.35, 0.425, 0.5.
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cases, even when the prior means are misspecified. In the three figures, only if the
new treatment is outstandingly good with prior mean 0.5 and the prior mean is
correctly specified in the design, small prior variance 0.05 can lead to lowest Np.
But under this condition, the Np which based on prior variance 0.1 is always the
second minimum and the difference between them and the minimum is less than 1.
If the prior means are not so high such as 0.2 or 0.35, no matter the prior means
are correctly specified or misspecified, medium level prior variance, 0.1, leads to
lowest Np in most of the cases.
From the 3 figures, we find the higher prior variance, the less effects of prior means
misspecifications on Np. In the figure 4.8 to figure 4.10, the lines of Np with prior
variance 0.15 are usually straight horizontal lines, and that with prior 0.1 have
variations in a small range, which is usually below 5; but that with prior variance
0.05 vary greatly. Moreover, when a treatment is misspecified as a higher prior
mean, Np decreases and when a treatment is misspecified a lower prior mean, Np
increases. For example, (α1, α
′
2) = (0.15, 0.15), prior variance is 0.05 and the true
mean is nonpromising level 0.2, if the prior mean applied in the design is correct
0.2, Np is 48.0276; if the prior mean is misspecified as 0.5, Np decreases to 35.3542,
the range is 12.6734. And the prior variance is 0.05 and true mean is very high 0.5,
if the prior mean used is correct 0.5, Np is 13.4081; if the prior mean is misspecified
as 0.2, Np increases to 16.4362, the range is 3.0281.
As a conclusion, when the true prior mean is high, whatever the prior variance is
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and whatever the prior mean is correct or misspecified, the expected number of
patients is always low. Small prior variance the sequential Bayesian designs are
sensitive to the misspecification of prior mean in the aspect of Np. But medium or
large prior variance designs, 0.1 or 0.15, are robust for the prior means misidenti-
fication.
4.2.2.2 Effects of Prior Means Misspecifications on Probability of False
Positive
The probability of false positive α1 is the probability to reject a promising treat-
ment. It is one of the constraints of the optimal designs. If the probability of
false positive changes greatly when the prior mean is misspecified, the proportion
of nonpromising designs among the treatments accepted is unstable. The design
is sensitive to prior means misspecifications. Obviously, the changes in α1 is an
important criterion to decide the robustness of sequential Bayesian designs. From
figure 4.11 to figure 4.13, we find that the probability of false positive decreases
with the increase of true prior mean. For example, in the plots, for the error rates
(0.15, 0.15) and prior variance 0.05, if prior mean is 0.2, α1 ranges from 0.14 to
0.29; if prior mean is 0.35, α1 range from 0.1 to 0.2; if prior mean 0.5, α1 ranges
from 0.06 to 0.12.
When the prior mean is correctly specified, the prior with variance 0.15, the largest
prior variance, always leads to the minimum of probability of false positive. On
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Figure 4.11: Plots of α1 When Correct Prior Mean is 0.2. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior mean
applied is 0.2, 0.275, 0.35, 0.425, 0.5. In the plots, alpha1 represents α1.
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Figure 4.12: Plots of α1 When Correct Prior Mean is 0.35. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior mean
applied is 0.2, 0.275, 0.35, 0.425, 0.5. In the plots, alpha1 represents α1.
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Figure 4.13: Plots of α1 When Correct Prior Mean is 0.5. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior mean
applied is 0.2, 0.275, 0.35, 0.425, 0.5. In the plots, alpha1 represents α1.
CHAPTER 4. EFFECTS OF PRIOR-MISSPECIFICATIONS 78
the contrary, the prior with smallest variance 0.05 leads to the highest probability
of false positive in most of the cases.
And the variation of α1, which is due to the misspecification of prior mean, de-
creases with the increasing of prior variance. In all the plots, the lines of α1 are all
nearly horizontal lines, if prior variance is 0.15; the lines of α1 have some variations
below 0.07, if prior variance is 0.1; the variation is relative large if prior variance is
as small as 0.05. Moreover, when the prior mean misspecified higher, α1 increases
and when the prior mean is misspecified lower, α1 decreases. For example, error
rates (0.15, 0.15) and prior variance 0.05, if the prior mean is 0.2, a nonpromising
treatment, when prior mean is correct, α1=0.145374, when prior mean is misspec-
ified as higher one 0.5, α1 increases to 0.28807. And if true prior mean is 0.5 and
variance is 0.05, when the prior mean is correctly specified, α1 is 0.12959; when the
prior mean is misspecified as a much lower one, 0.2, α1 decreases to 0.06488, but
both of the values are relative low.
Generally speaking, the sequential Bayesian decision theoretic designs are robust
to misspecification if the prior mean is high or the prior variance is high.
4.2.2.3 Effects of Prior Means Misspecifications on Probability of False
Negative
The probability of false negative (α′2) is the probability to reject a promising treat-
ment. It is one of the constraints of the optimal designs. If the probability of false
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negative changes greatly when the prior mean is misspecified, the proportion of
promising designs among the rejected treatments is unstable. The design is sensi-
tive to prior means misspecifications. Obviously, the changes in α′2 is an important
criterion to decide the robustness of sequential Bayesian designs. We find that
the probability of false negative increases with the increase of true prior mean. For
example, in the figure 4.14 to figure 4.16, for the error rates (0.15, 0.15) and prior
variance 0.05, if prior mean is 0.2, α′2 ranges from 0.021 to 0.05; if prior mean is
0.35, α′2 range from 0.09 to 0.16; if prior mean 0.5, α
′
2 ranges from 0.14 to 0.24.
For all combinations of error rates, no matter the prior mean is correctly specified
or misspecified, if the prior variance is large 0.15, the probability of false negative
is always the lowest; if the prior variance is small 0.05, this probability is always
the highest; if the prior variance is medium 0.1, and the probability is in between.
When the prior mean is misspecified, the probability of false negative varies. And
the variation decreases with the increasing of prior variance. If the prior mean is
misspecified as a higher one, α′2 decrease in most of the cases; if the prior mean is
misspecified as a lower one, α′2 increases. For example, for error rates (0.15, 0.15)
and prior variance 0.05, if prior mean is 0.2 a small one, α′2 is 0.043116, if prior
mean is misspecified as a higher one, 0.5, α′2 decreases to 0.01991; if prior mean is
0.5, α′2 is 0.14204, if the prior mean is misspecified as 0.2, α
′
2 increases to 0.237438.
As a conclusion, the higher the prior mean is, the lower probability to be rejected
falsely. And the higher the prior variance is, the lower probability of false nega-
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Figure 4.14: Plots of α′2 When Correct Prior Mean is 0.2. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior mean
applied is 0.2, 0.275, 0.35, 0.425, 0.5. In plots alpha2prime represents α′2.
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Figure 4.15: Plots of α′2 When Correct Prior Mean is 0.35. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior mean
applied is 0.2, 0.275, 0.35, 0.425, 0.5. In plots alpha2prime represents α′2.
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Figure 4.16: Plots of α′2 When Correct Prior Mean is 0.5. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior mean
applied is 0.2, 0.275, 0.35, 0.425, 0.5. In plots alpha2prime represents α′2.
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tive, no matter the prior mean is correctly specified or misspecified. In addition, a
treatment with low prior mean is misspecified as the one with higher prior mean,
the probability to be falsely rejected is decreased, and verse versus.
4.2.3 Effects of Prior Variances Misspecifications
In this section, we test the effect of prior variances misspecification. For each
variance, we let the mean vary in three values, 0.2 (nonpromising), 0.35 (promising)
and 0.5 (very successful). And there are five possible values of prior variance, from
the very small one to larger one, 0.05, 0.075, 0.1, 0.125 and 0.15.
4.2.3.1 Effects of Prior Variances Misspecifications on Expected Number
of Patients
From figure 4.17 to figure 4.19, we find no matter the prior variance is correctly
specified or misspecified, Np decreases with the increases of prior mean. The lines
of Np is always highest if the prior mean is 0.2; the lines of Np is always lowest if
the prior mean is 0.5; and the expected number is in between if the prior mean is
0.35. Moreover, the effects of prior variances misspecifications on Np decrease with
the increase of prior mean. The values of Np range from 35 to 49, if the prior mean
is 0.2; it ranges from 15 to 26, if the prior mean is 0.35; and it ranges from 11 to
17, if the prior mean is 0.5. In all the plots, the lines of Np with prior mean is 0.5,
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always like straight horizontal lines, but the lines of prior mean 0.2 vary greatly.
When the prior mean is low, Np increases with the decrease of prior variance and
Np increase with the decrease of prior variance.
In addition, the designs are more robust if the correct prior variance is higher. In
the three figures, we find the variation of each line decreases with the increase of
prior variances.
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Figure 4.17: Plots of Np When Correct Prior Variance is 0.05. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2).. Group =1, 2, 3, 4, 5 represents the prior variance
applied is 0.05, 0.075, 0.1, 0.125, 0.15.
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Figure 4.18: Plots of Np When Correct Prior Variance is 0.1. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior variance
applied is 0.05, 0.075, 0.1, 0.125, 0.15.
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Figure 4.19: Plots of Np When Correct Prior Variance is 0.15. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior variance
applied is 0.05, 0.075, 0.1, 0.125, 0.15.
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4.2.3.2 Effects of Prior Variances Misspecifications on Probability of
False Positive
α1 is the probability of false positive. From figure 4.20 to figure 4.22, we find
the probability of false positive decreases with the increase of true prior variance.
For example, for the error rate (0.15, 0.15) and the prior mean 0.5, α1 varies from
0.12959 to 0.177525, if the prior variance is very small, 0.05; α1 varies from 0.114963
to 0.167667, if the prior variance is 0.1; and α1 varies from 0.082995 to 0.127278,
if the prior variance is large 0.15.
From the plots we also find the effects of prior variances misspecifications decrease
with the increase of correct prior variances. And if the true prior variance is large
0.15, when the prior mean is small 0.2, the probability of false positive is always
lower than the others even if the prior variance is misspecified; if the prior variance
is small 0.05, when the prior mean is high 0.5, the probability of false positive is
always lower than the others even the prior is misspecified. For all level of true
prior variance, if the prior variance is misspecified as a higher one, the probability
of false positive increases, while if the prior variance is misspecified as a lower one,
the probability of false positive decreases.
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Figure 4.20: Plots of α1 When Correct Prior Variance is 0.5. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior variance
applied is 0.05, 0.075, 0.1, 0.125, 0.15.
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Figure 4.21: Plots of α1 When Correct Prior Variance is 0.1. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior variance
applied is 0.05, 0.075, 0.1, 0.125, 0.15.
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Figure 4.22: Plots of α1 When Correct Prior Variance is 0.15. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior variance
applied is 0.05, 0.075, 0.1, 0.125, 0.15.
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4.2.3.3 Effects of Prior Variances Misspecifications on Probability of
False Negative
α′2 is the probability of false negative. From figure 4.23 to figure 4.25, we find α
′
2
decreases with the increase of true prior variance. For error rates (0.15,0.15) and
prior mean 0.2, α′2 ranges from 0.011729 to 0.043116, if the true prior variance
is 0.05; α′2 ranges from 0.00506 to 0.02099, if the true prior variance is 0.1; α
′
2
ranges from 0.000666 to 0.002968, if the true prior variance is 0.15. The higher the
true prior variances imply the lower probabilities of false negative. In addition, the
effects of prior variances misspecifications decrease with the increase of correct prior
variances. It implies that the designs are more robust, if the true prior variances
are large.
No matter the prior variance is correctly specified or misspecified, the treatment
with lowest prior mean always leads to the lowest probability of false negative
and smallest variation caused by misspecification of prior variance. Moreover, if
the prior variance is misspecified as a higher one, the probability of false negative
decreases; if the prior variance is misspecified as a lower one, the probability of
false negative increases.
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Figure 4.23: Plots of α′2 When Correct Prior Variance is 0.05. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior variance
applied is 0.05, 0.075, 0.1, 0.125, 0.15.
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Figure 4.24: Plots of α′2 When Correct Prior Variance is 0.1. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior variance
applied is 0.05, 0.075, 0.1, 0.125, 0.15.
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Figure 4.25: Plots of α′2 When Correct Prior Variance is 0.15. The four plots from left to
right from up to down are based on the four combinations of error rates (α1, α
′
2) =(0.15,
0.15), (0.15,0.20),(0.2, 0.15), (0.2, 0.2). Group =1, 2, 3, 4, 5 represents the prior variance
applied is 0.05, 0.075, 0.1, 0.125, 0.15.




In the thesis, we carries out numerical analysis to detect the effects of prior-
misspecifications on Bayesian sequential designs and sequential Bayesian decision
theoretic designs. For both of the two widely used designs, we test the effects
of prior means misspecifications and prior variances misspecifications respectively.
And we used two examples to show the effects of prior means misspecifications on
the cutoff boundaries.
For the Bayesian sequential design, we use the expected number of patients (EN),
probability of rejection (p−) and probability of acceptance (p+) as the criteria to
decide whether the misspecifications of priors affect the design. In general, when
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the prior is correctly specified, Bayesian sequential designs are effective in using
reasonable EN to reject nonpromising treatment with high p− and low p+ or accept
promising treatment with low p− and high p+.
Bayesian sequential designs are robust to misspecifications of prior variances and
they are robust to the misspecifications of prior means if the prior variances are
large. But for the other situations, the sequential designs are sensitive to prior
means misspecifications. When the prior mean is misspecified, the number of
EN usually becomes larger. If the prior mean is misspecified as a larger one,
p− decreases and p+ increases; if the prior mean is misspecified as a lower one,
p− increases and p+ decreases. However, the effects of misspecifications could be
decreased by the increase of prior variance.
For the sequential Bayesian decision theoretic design, we use the expected number
of patients to test (Np), probability of false positive (α1) and probability of false
negative (α′2) as the criteria to decide whether the misspecifications of priors affect
the design. In general, when the prior is correctly specified, sequential Bayesian
decision theoretic designs are effective to make decisions using reasonable Np with
low probability of false positive and false negative.
The sequential Bayesian decision theoretic designs are robust to the misspecifica-
tions of prior means and misspecifications of prior variances, if the true prior means
or the true prior variances are large respectively. If the prior mean is misspecified
as a higher one, Np decreases, α1 increases and α
′
2 decreases; if the prior mean is
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misspecified as a lower one, Np increases, α1 decreases and α
′
2 increases. However,
the effects of prior means misspecifications could be decreased if the prior variances
are large. If the prior variance is misspecified as a higher one, the α1 increases and
α′2 decrease; and if the prior variance is misspecified as a lower one, the α1 decreases
and α′2 increases. Moreover, the effects of prior variances misspecifications decrease
with the increase of prior means.
As a conclusion for both of the two kinds of designs, we find the prior means play
much more important roles than the prior variances do. When the prior means are
high, the designs are always robust. It implies the designs are effective to accept
promising treatment no matter the priors are correct or misspecified. If the prior
mean is lower, the effects of misspecifications could be decreased by increasing of
the prior variances. In practice, we should be careful to decide the prior means in
phase IIA clinical trials.
5.2 Discussion
The phase II designs are important research areas of statistical methodologies in
clinical trials. In the thesis, the sensitivity tests are only limited to the sequential
designs. In the future, the sensitivity tests could be extended to one-stage designs,
two-stage designs or multi-stage designs. Moreover, the misspecifications of cost
functions or gain functions are valuable to be tested. In addition, the sensitivity
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characters should be proved by mathematics theories. Finally, the response of
each treatment need not be limited to binary, it could be extended to Multinomial


















































} MU ML bound<-matrix(0,31,3) bound[,1]<-MU[,1] bound[,2]<-ML[,2]
bound[,3]<-MU[,2] bound write.table(bound,file = "D:\\bayesian
sequential design\\program 16\\bound16-1.xls", sep = "\t" , na =
NA) write.table(MU,file = "D:\\bayesian sequential design\\program
16\\MU.txt", sep = "\t" , na = NA) write.table(ML,file =
"D:\\bayesian sequential design\\program 16\\ML.txt", sep = "\t"









t1<-0 t2<-0 t3<-0 t4<-0
y40<-MU[n-9,2] y39<-y40-1 y38<-y39-1
y37<-y38-1 while (y37<=y38) {
if (y37<MU[28,2] && y37>ML[28,2])
{ y36<-y37-1 while (y36<=y37) {
if (y36<MU[27,2] && y36>ML[27,2])
{ y35<-y36-1 while (y35<=y36) {
if (y35<MU[26,2] && y35>ML[26,2])
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{ y34<-y35-1 while (y34<=y35) {
if (y34<MU[25,2] && y34>ML[25,2])
{ y33<-y34-1 while (y33<=y34) {
if (y33<MU[24,2] && y33>ML[24,2])
{ y32<-y33-1 while (y32<=y33) {
if (y32<MU[23,2] && y32>ML[23,2])
{ y31<-y32-1 while (y31<=y32) {
if (y31<MU[22,2] && y31>ML[22,2])
{ y30<-y31-1 while (y30<=y31) {
if (y30<MU[21,2] && y30>ML[21,2])








if (y27<MU[18,2] && y27>ML[18,2])
{ y26<-y27-1 while (y26<=y27) {
if (y26<MU[17,2] && y26>ML[17,2])




if (y24<MU[15,2] && y24>ML[15,2])
{ y23<-y24-1 while (y23<=y24) {
if (y23<MU[14,2] && y23>ML[14,2])
{ y22<-y23-1 while (y22<=y23) {
if (y22<MU[13,2] && y22>ML[13,2])
{
y21<-y22-1
while (y21<=y22) {if (y21<MU[12,2] && y21>ML[12,2]) {y20<-y21-1
while (y20<=y21) {
if (y20<MU[11,2] && y20>ML[11,2])
{y19<-y20-1 while (y19<=y20) {
if (y19<MU[10,2] && y19>ML[10,2])
{ y18<-y19-1 while (y18<=y19) {
if (y18<MU[9,2] && y18>ML[9,2])
{ y17<-y18-1 while (y17<=y18) { if (y17<MU[8,2] && y17>ML[8,2]) {
y16<-y17-1
while (y16<=y17)








if (y14<MU[5,2] && y14>ML[5,2])
{
y13<-y14-1 while (y13<=y14) {





if (y12<MU[3,2] && y12>ML[3,2])
{
y11<-y12-1
while(y11 <= y12) {
if(y11 < MU[2, 2] && y11 > ML[2, 2]) {
y10 <- y11 - 1
while(y10 <= y11) {
if(y10 == 1)
{
t1 = t1 + 1
}
if (y10 == 2) {
t2 = t2 + 1
}
if(y10 == 3) {
t3 <- t3 + 1
}
if(y10 == 4) {
t4 <- t4 + 1
}
y10 <- y10 + 1
}
}
y11 <- y11 + 1
} } y12<-y12+1 } } y13<-y13+1 } } y14<-y14+1 }} y15<-y15+1 } }
y16<-y16+1 } } y17<-y17+1 }} y18<-y18+1 }} y19<-y19+1 } }
y20<-y20+1 } } y21<-y21+1 } } y22<-y22+1 } } y23<-y23+1 } }
y24<-y24+1 } } y25<-y25+1 } } y26<-y26+1 } } y27<-y27+1 } }
y28<-y28+1 }} y29<-y29+1 } } y30<-y30+1 } } y31<-y31+1 }}





pplus[n-9,]<-c(n,t2,t3,t4,pplusn) pplusn n t2 t3 t4
write.table(pplus,file = "D:\\bayesian sequential design\\program
16\\pplus.xls", sep = "\t" , na = NA)
#get the upper and lower boundary in sequential Bayesian decision
theoretic designs# nMAX<-40 nMIN<-10 thetas<-0.35 a<-0.4 b<-1.6




























































































N<- array(5, dim = c(2,nMAX,nMAX+1))










































#get the misspecified upper and lower boundary #
B<-matrix(100,nMAX,3) B[,1]<-c(1:nMAX) B[nMAX,2]<-xnMAX-1

































l<-1 c1<-10 while (c1<=100) { c2<-5 while (c2<=95) {









N<- array(5, dim = c(2,nMAX,nMAX+1))











































#get the upper and lower boundary #
B<-matrix(100,nMAX,3) B[,1]<-c(1:nMAX) B[nMAX,2]<-xnMAX-1































































C2<-matrix(0,nMAX,nMAX+1) n<-nMAX s<-1 while (s<=xnMAX) {
C2[n,s]<-1-pbeta(thetas,a+s-1,b+nMAX-s+1)
s<-s+1



























} C1 C2 ppm<-C1[1,2]*a/(a+b)+C1[1,1]*b/(a+b)
pmp<-C2[1,2]*a/(a+b)+C2[1,1]*b/(a+b) ppp<-p-pmp pmm<-1-p-ppm p ppm
pmp ppp pmm N0<-1+N[2,1,2]*a/(a+b)+N[2,1,1]*b/(a+b)
Et<-N0-c1*ppm-c2*pmp Et alpha1<-ppm/(ppm+ppp)
alpha2prime<-pmp/(pmp+pmm) alpha2<-pmp/(1-pmm) alpha1 alpha2prime




c2<-c2+10 } c1<-c1+10 } cost
D3<-matrix(100,100,13) n<-1 t<-1 while (n<=100) {







write.table(cost,file = "D:\\research\\my program\\theoretic
design\\program 2\\cost23.xls", sep = "\t" , na = NA)
write.table(D3,file = "D:\\research\\my program\\theoretic
design\\program 2\\cost23.xls", sep = "\t" , na = NA, append=T)
min(D3[,8])
D4<-matrix(100,100,13) n<-1 t<-1 while (n<=100) {







write.table(D4,file = "D:\\research\\my program\\theoretic
design\\program 2\\cost24.xls", sep = "\t" , na = NA)
min(D4[,8])
D5<-matrix(100,100,13) n<-1 t<-1 while (n<=100) {







write.table(D5,file = "D:\\research\\my program\\theoretic






#this is true prior#
a<-0.4 b<-1.6
p<-1-pbeta(thetas,a,b)
# but true as (a,b)=(0.4,1.6), so use the bound cost and and N of
program 2#
c1<-30 c2<-45




design\\program 3\\N351.txt"), ncol=nMAX+1, byrow=TRUE)




















































alpha2<-pmp/(1-pmm) alpha1 alpha2prime alpha2
Nv<-(1-alpha1*(1-alpha2))/(1-alpha2)/p Nv Np<-Et*Nv Np N0 p ppm
pmp ppp pmm
cost<-c(c1,c2,thetas,alpha1,alpha2prime,alpha2,Et,Nv,Np,p,ppm,pmp,ppp,pmm)
write.table(cost,file = "D:\\research\\my program\\theoretic
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